107
Views
20
CrossRef citations to date
0
Altmetric
Original Research

Inhibition of EZH2 and EGFR produces a synergistic effect on cell apoptosis by increasing autophagy in gastric cancer cells

, , , , &
Pages 8455-8463 | Published online: 29 Nov 2018

References

  • CharalampakisNEconomopoulouPKotsantisIMedical management of gastric cancer: a 2017 updateCancer Med20187112313329239137
  • KimKHRobertsCWTargeting EZH2 in cancerNat Med201622212813426845405
  • RogawskiDSGrembeckaJCierpickiTH3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor developmentFuture Med Chem20168131589160727548565
  • JiangTWangYZhouFGaoGRenSZhouCPrognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysisOncotarget2016744584459726683709
  • MccabeMTOttHMGanjiGEZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutationsNature2012492742710811223051747
  • ChenYTZhuFLinWRYingRBYangYPZengLHThe novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-ACancer Chemother Pharmacol201677475776526898301
  • KoppensMABounovaGCornelissen-SteijgerPLarge variety in a panel of human colon cancer organoids in response to EZH2 inhibitionOncotarget2016743698166982827634879
  • KhanMWaltersLLLiQCharacterization and pharmacologic targeting of EZH2, a fetal retinal protein and epigenetic regulator, in human retinoblastomaLab Invest201595111278129026280220
  • ZengDLiuMPanJBlocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cellsOncotarget201782339627926488
  • WieduwiltMJMoasserMMThe epidermal growth factor receptor family: biology driving targeted therapeuticsCell Mol Life Sci200865101566158418259690
  • ValentiniAMPirrelliMCarusoMLEGFR-targeted therapy in colorectal cancer: does immunohistochemistry deserve a role in predicting the response to cetuximab?Curr Opin Mol Ther200810212418386224
  • RusnakDWAlligoodKJMullinRJAssessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell linesCell Prolif200740458059417635524
  • RielyGJThe use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutationsLung Cancer200860Suppl 2S19S2218513580
  • DhillonSGefitinib: a review of its use in adults with advanced non-small cell lung cancerTarget Oncol201510115317025637458
  • MorishitaAGongJMasakiTTargeting receptor tyrosine kinases in gastric cancerWorld J Gastroenterol201420164536454524782606
  • PrahalladASunCHuangSUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFRNature2012483738710010322281684
  • GirgertREmonsGGründkerC17β-estradiol-induced growth of triple-negative breast cancer cells is prevented by the reduction of GPER expression after treatment with gefitinibOncol Rep20173721212121827959426
  • SongZHuangSYuHSynthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC)Eur J Med Chem201713332933928395219
  • AzadNZahnowCARudinCMBaylinSBThe future of epigenetic therapy in solid tumours – lessons from the pastNat Rev Clin Oncol201310525626623546521
  • ChouTCDrug combination studies and their synergy quantification using the Chou-Talalay methodCancer Res201070244044620068163
  • KatonaBWLiuYMaAJinJHuaXEZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cellsCancer Biol Ther201415121677168725535899
  • GrinshteinNRiosecoCCMarcellusRSmall molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cellsOncotarget2016737593605937627449082
  • PetragliaFSinghAACarafaVCombined HAT/EZH2 modulation leads to cancer-selective cell deathOncotarget2018939256302564629876013
  • OralOAkkocYBayraktarOGozuacikDPhysiological and pathological significance of the molecular cross-talk between autophagy and apoptosisHistol Histopathol201631547926680630
  • RubinBPDebnathJTherapeutic implications of autophagy-mediated cell survival in gastrointestinal stromal tumor after treatment with imatinib mesylateAutophagy2010681190119120930540
  • RavegniniGSammariniGNanniniMGastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosisAutophagy201713345246328055310
  • RubinsteinADEisensteinMBerYBialikSKimchiAThe autophagy protein Atg12 associates with antiapoptotic Bcl-2 family members to promote mitochondrial apoptosisMol Cell201144569870922152474
  • PeiJDengJYeZAbsence of autophagy promotes apoptosis by modulating the ROS-dependent RLR signaling pathway in classical swine fever virus-infected cellsAutophagy201612101738175827463126
  • ZhuJYuWLiuBEscin induces caspase-dependent apoptosis and autophagy through the ROS/p38 MAPK signalling pathway in human osteosarcoma cells in vitro and in vivoCell Death Dis2017810e311329022891
  • BoothLATavallaiSHamedHACruickshanksNDentPThe role of cell signalling in the crosstalk between autophagy and apoptosisCell Signal201426354955524308968